DoW Toxic Exposures Clinical Trial Award

General Information Document Type: Grants Notice Funding Opportunity Number: HT942526TERPCTA Funding Opportunity Title: DoW Toxic Exposures Clinical Trial Award Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Grant Category of Funding Activity: Science and Technology and other Research and Development Category Explanation: Expected Number of Awards: 1 Assistance Listings: 12.420 -- Military Medical Research and Development Cost Sharing or Matching Requirement: No Version: Synopsis 3 Posted Date: May 21, 2026 Last Updated Date: May 21, 2026 Original Closing Date for Applications: Nov 19, 2026 Current Closing Date for Applications: Nov 19, 2026 Archive Date: Dec 19, 2026 Estimated Total Program Funding: $ 4,500,000 Award Ceiling: $ Award Floor: $ Eligibility Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: Additional Information Agency Name: Defense Health Agency Contracting Activity - DHACA Description: Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/ knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann Link to Additional Information: Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact: eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org eBRAP Help Desk